Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 6,882 matching trials from the live ClinicalTrials.gov search.
Conditions
Social Anxiety Disorder (SAD)
Interventions
BVR-100, BES-100
Device
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orlando, Florida • Boston, Massachusetts • Saint Charles, Missouri + 2 more
Conditions
Influenza, Human
Interventions
mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
100
States / cities
Athens, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
18
States / cities
San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Corabotase, Placebo, Corabotase dose A, Corabotase dose B
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
Conditions
CTX
Interventions
Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Conditions
Type 2 Diabetes
Interventions
Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Cystic Fibrosis
Interventions
Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Drug · Other
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses

NCT07076160
Conditions
Visual Acuity, Presbyopia
Interventions
INFUSE® One Day Multifocal, ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
7
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 3 more
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
404
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
Conditions
Acute Pancreatitis
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Conditions
Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
390
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

NCT02121860
Conditions
Hepatic Impairment, Liver Diseases, Digestive System Diseases
Interventions
IDN-6556
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida
Conditions
Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation
Interventions
Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Anchorage, Alaska • Phoenix, Arizona • Santa Monica, California + 27 more
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

Continuation Protocol for Obstructive Sleep Apnea (OSA)

NCT06566820
Conditions
OSA
Interventions
Aroxybutynin and Atomoxetine
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chandler, Arizona + 80 more
Conditions
Phobic Disorders
Interventions
JNJ-42165279, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
La Jolla, California • Hartford, Connecticut • Orlando, Florida + 10 more
Conditions
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
everolimus, Placebo, vinorelbine, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more
Conditions
Cystic Fibrosis
Interventions
Inhaled mannitol, Placebo Comparator: Arm B - Control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 99 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
288
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Conditions
Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Wilmington, Delaware + 13 more
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Bradenton, Florida + 9 more